Voronoi, Inc. (KOSDAQ:310210)

Market Cap	2.21T
Revenue (ttm)	n/a
Net Income (ttm)	-40.15B
Shares Out	17.99M
EPS (ttm)	-2,261.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63,837
Average Volume	123,707
Open	122,400
Previous Close	122,200
Day's Range	119,000 - 123,500
52-Week Range	63,000 - 153,000
Beta	1.89
RSI	51.90
Earnings Date	Aug 12, 2025

About Voronoi

Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company’s products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multipl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 139
• Stock Exchange: KOSDAQ
• Ticker Symbol: 310210